DLRC launches Regulatory Spark to give early-stage innovators an investor-ready route to clinic

New service brings senior regulatory expertise into the early development window, when strategic decisions can have the greatest impact.

DLRC, an award-winning global regulatory and market access consultancy that supports the development and licensing of pharmaceutical, biotech, advanced therapy, and medtech products worldwide, launches Regulatory Spark, a new fixed-fee, fast-turnaround service created for early-stage innovators.

Regulatory Spark is designed to help founder-led biotech companies, scientific founders, academic spinouts, and tech transfer teams understand their likely route to the clinic before key funding, development, or investor decisions are made. In just 1 to 2 weeks, innovators receive a practical regulatory toolkit covering high-level product classification, a path-to-clinic roadmap, data requirements, the regulatory risks that matter most, and an investor-ready summary.

The greatest development risks often arise at the very beginning. Founders can make pivotal decisions on product classification, CMC and non-clinical development before seeking regulatory advice, only to discover later that course corrections are costly, time-consuming and disruptive. Yet the strategic regulatory support needed to avoid these pitfalls is often priced well beyond early-stage budgets, creating a gap between when expert guidance is most valuable and when companies can realistically afford it.

Regulatory Spark closes that gap. It packages senior, multi-region regulatory insight into a transparent, founder-facing product, helping innovators answer the questions investors most often ask: “What is your regulatory pathway?” and “What data do you need?”

Key features of the Regulatory Spark service include:

• Product Classification & Pathway: A high-level assessment of how the asset is likely to be regulated (drug, biologic or ATMP).
• Path-to-Clinic Roadmap: A simple visual roadmap from the current position through to CTA / IND readiness, with indicative timelines.
• Top Regulatory Risks: An outline of the regulatory and development risks that matter most.
• Data Requirements: A high-level overview of the non-clinical and CMC data likely to be needed before first-in-human studies.
• Investor-Ready Summary: A concise summary that can be shared with investors, accelerators and grant bodies.
• Founder Discussion: A 60-minute review call with a senior DLRC consultant to walk through the roadmap, answer questions and agree on next steps.

As programmes develop, Regulatory Spark offers a clear upgrade path into The Regulatory Catalyst and wider DLRC support for deeper preclinical, CMC, clinical development strategy and CTA or IND planning.

DLRC’s approach is practical and outcome-focused. It helps early-stage teams de-risk before they spend, raise with credibility, and move at founder speed, turning early-stage uncertainty into investor confidence.

Discover more about the new service offering here.

Hear from DLRC’s Chief Regulatory Officer, Wafa Bouaziz:

Regulators recommend early engagement with regulatory consulting firms; nine out of ten biotech start-ups never reach the market; Regulatory Spark gives founders senior, multi-region regulatory direction at a seed-stage price and in a seed-stage timeframe. This will also give investors’ confidence in the regulatory route to clinic.